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A B S T R A C T
Background
This is an updated version of the original Cochrane review published in 2010, Issue 1. Seizures after stroke are an important clinical
problem, and they may be associated with poor outcome. The effects of antiepileptic drugs for the primary and secondary prevention
of seizures after stroke remain unclear.
Objectives
We aimed to assess the effects of antiepileptic drugs for the primary and secondary prevention of seizures after stroke.
Search methods
We searched the Specialised Registers of the Cochrane Epilepsy Group (12 August 2013) and the Cochrane Stroke Group (12 August
2013), the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library 2013, Issue 7), and MEDLINE (OVID,
1946 to 12 August 2013). We also checked the reference lists of articles retrieved from these searches.
Selection criteria
Randomised and quasi-randomised controlled trials in which participants were assigned to treatment or control group (placebo or no
drug).
Data collection and analysis
Two review authors independently screened all the titles, abstracts, and keywords of publications identified by the searches to assess
their eligibility, and both review authors assessed their suitability for inclusion according to prespecified selection criteria. We included
only one study for data collection and analysis.
Main results
We found only one trial that fulfilled the study inclusion criteria of comparison of the effects of an antiepileptic drug with placebo
(or no drug) for the primary or secondary prevention of seizures after stroke. This was a prospective randomised, double-blind,
placebo-controlled trial comparing valproic acid with placebo for primary prevention of seizures in 72 adults (over 18 years of age)
with spontaneous non-aneurysmal, non-traumatic intracerebral haemorrhage; no statistically significant difference in outcome (seizure
occurrence at one year) was demonstrated between groups.
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Authors’ conclusions
Currently, there is insufficient evidence to support the routine use of antiepileptic drugs for the primary or secondary prevention of
seizures after stroke. Further well-conducted research is needed for this important clinical problem.
P L A I N L A N G U A G E S U M M A R Y
Is there evidence to support the use of antiepileptic drugs for the primary and secondary prevention of seizures after stroke?
Background
Seizures (epileptic attacks) after stroke are a major clinical problem. It is unclear whether antiepileptic drugs are effective in preventing
seizures after stroke in adults. This review searched in August 2013 for high quality evidence to help clarify this problem. We found
only one high quality clinical trial that looked at whether antiepileptic drugs may be more effective than placebo in preventing seizures
after stroke.
Study Characteristics
The only study that was included in this review was Gilad 2011. This was a prospective randomised, double-blind, placebo controlled
trial studying the efficacy of valproic acid versus placebo in the primary prevention of seizure in 72 adults (over 18 years of age) with
spontaneous non-aneurysmal, non-traumatic intracerebral haemorrhage. Patients were randomly allocated to either the treatment or
the placebo group with active treatment lasting one month; the primary outcome was seizure occurrence at one year. People with very
early seizures (within 24 hours of onset of haemorrhage) were excluded from the study. Seizure was diagnosed on the basis of eye-
witness evidence from staff, relatives or other eye witnesses.
Quality Of The Evidence
There does not appear to be bias in Gilad 2011, on the basis of the information available within the study.
Key Results
Gilad 2011 did not show a statistically significant benefit when comparing valproic acid with placebo for the primary prevention
of seizures after spontaneous non-aneurysmal, non-traumatic intracerebral haemorrhage. Currently, therefore, there is not enough
evidence to justify the routine use of antiepileptic drugs to prevent seizures after stroke (evidence current to 08/2013). Further research
is needed for this important clinical problem.
B A C K G R O U N D
Stroke is a major health problem in both the developed and de-
veloping world. In industrialised countries, it is the third most
common cause of death after ischaemic heart disease and cancers,
and almost half of all stroke survivors are left with a permanent
handicap (Bamford 1991). Stroke mainly affects the older genera-
tion, although about 25% of all strokes occur in people under the
age of 65, and about 1% in people under the age of 30.
Cerebrovascular disease is the most commonly identified cause
of acquired epilepsy. Post-stroke seizures account for 11% of
all epilepsy, 22% of all cases of status epilepticus, and 55% of
newly diagnosed seizures amongst older people (Camilo 2004;
DeLorenzo 1996; Herman 2002). The reported incidence of
post-stroke seizures varies widely between epidemiological stud-
ies, ranging from 2% to 33% for early seizures (within the first
14 days) and 3% to 67% for later seizures (Camilo 2004). This
is mainly due to the varying methods of case ascertainment and
definitions used in relation to the timing of post-stroke seizures.
According to epidemiological guidelines developed by the Inter-
national League Against Epilepsy (ILAE 1981) seizures occurring
within the first week of stroke are defined as ’early seizures’, and
those occurring after the first week are defined as ’late seizures’.
Using this definition, approximately 2% to 6% of people with
stroke suffer early seizures (Lamy 2003; So 1996), and 3% to 5%
suffer late seizures (Lamy 2003; So 1996). In the longer term, one
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community-based study found that the cumulative actuarial risk
of having a post-stroke seizure was 4.2% at one year and 11.5%
at five years (Burn 1997).
Development of late seizures is more common in people who have
experienced early seizures (risk of about 30% (Kilpatrick 1990)).
Moreover, development of post-stroke epilepsy (that is, recurrent
seizures) is more common in people who have experienced late
seizures, with a risk of about 50% (Olsen 2001), than for those
with early seizures where the risk is about 30% (Olsen 2001; Sung
1990). Possible risk factors for post-stroke seizures (Burn 1997;
Camilo 2004; Kwan 2007; Lamy 2003; Shinton 1988) include
the following:
(1) stroke subtype: cerebral haemorrhage (especially subarachnoid
haemorrhage);
(2) location of the lesion: cortical involvement, stroke occurring
within the carotid artery territory;
(3) stroke severity (but correlation may be weaker after adjusting
for stroke subtype and location);
(4) occurrence of post-stroke bacterial infections.
The pathophysiology of early and late post-stroke seizures is be-
lieved to be different. In the first few days following an ischaemic
brain lesion, cellular biochemical dysfunction can lead to cortical
excitability and seizure activity (Kessler 2002). Acute ischaemia
leads to a massive release of glutamate, causing excessive activation
of glutamate receptors. This process is believed to be responsible
for secondary neuronal injury and epileptogenesis in ischaemic
stroke (Sun 2001; Sun 2002). Within the ischaemic penumbra,
a mixed population of dead, dying, and surviving neurones can
become the underlying substrate for ischaemia-induced epilepto-
genesis (Kessler 2002). In contrast, late seizures may be caused
by development of gliosis and meningocerebral cicatrices, with
changes in membrane properties, deafferentation, selective neu-
ronal loss, and collateral sprouting (Camilo 2004). This can result
in cortical hyperexcitability and neuronal synchrony sufficient to
cause seizures (Kessler 2002).
The relationship between post-stroke seizures and outcome re-
mains unclear. Several studies have found that post-stroke seizures
may predict worse functional outcome (Menon 2009), but many
of these studies have not adjusted for important covariates such as
stroke severity (Camilo 2004). One large study (Labovitz 2001)
showed that, before adjusting for stroke severity, occurrence of
early post-stroke seizures increased the risk of 30-day mortality
(odds ratio (OR) 4.3, 95% confidence interval (CI) 1.5 to 12.5).
However, after adjusting for stroke severity using the National
Institutes of Health Stroke Scale (NIHSS) score, this association
was not statistically significant (OR 2.1, 95% CI 0.6 to 7.1). In
another large community-based study, early post-stroke seizures
actually predicted a better neurological outcome (Reith 1997).
There is also some evidence that post-stroke seizures may signifi-
cantly affect health-related quality of life (Leidy 1999) but a large
prospective study did not find any adverse effect on rehabilitation
outcome as measured by the Barthel Index or the Rivermead Mo-
bility Index (Paolucci 1997).
Currently, it is unclear whether antiepileptic drugs should be rou-
tinely prescribed for the primary and secondary prevention of
seizures after stroke.
O B J E C T I V E S
We aimed to assess the effects of antiepileptic drugs (AEDs) for
the primary and secondary prevention of seizures after stroke.
(1) For the question of primary prevention, we aimed to examine
whether AEDs reduce the likelihood of seizures in people who
have had a stroke but have not had a seizure.
(2) For the question of secondary prevention, we aimed to examine
whether AEDs reduce the likelihood of further seizures in people
who have had a stroke and at least one post-stroke seizure.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered all randomised and quasi-randomised controlled
trials in which participants were assigned to ’treatment’ or ’control’
group (that is, placebo or no drug).
Types of participants
We used the World Health Organization definition of stroke for
this review (WHO 1989).We considered all studies that recruited
participants with a new neurological deficit consistent with a clin-
ical diagnosis of stroke. We considered studies that included par-
ticipants with either ischaemic or haemorrhagic stroke, but we ex-
cluded studies that only recruited participants with subarachnoid
haemorrhage, subdural haemorrhage, extradural haemorrhage, or
other non-stroke diagnoses such as tumour- or infection-related
infarction or haemorrhage.We also excluded studies that recruited
only participants who had undergone any type of neurosurgery.
The management of these excluded patient groups is likely to be
substantially different from the generality of people with stroke.
For studies which have reported the results for a mixture of par-
ticipant groups, we attempted to separate them and identify those
which were relevant to the participant groups of interest. When
we found that this was not possible, we excluded the studies. We
included participants of all ages suffering any seizure type.
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Types of interventions
AEDs were any of those listed on the Cochrane Epilepsy
Group information page, including carbamazepine, clobazam,
clonazepam, diazepam, ethosuximide, gabapentin, lamotrigine,
levetiracetam, lorazepam, oxcarbazepine, phenytoin, phenobarbi-
tone, primidone, sodium valproate, tiagabine, topiramate, viga-
batrin, and zonisamide. We considered all trials in which the in-
tervention was compared with a placebo or with no drug. We ex-
cluded studies comparing two AEDs.
Types of outcome measures
Primary outcome measures
Proportion of participants who experienced seizures in the sched-
uled follow-up period. In cases where seizures have occurred, we
noted their nature (generalised or focal) and timings if reported.
As described in the Background, seizures occurring within the first
week of stroke were defined as ’early seizures’ and those occurring
after the first week were defined as ’late seizures’ (ILAE 1981).
Occurrence of recurrent late seizures was defined as ’post-stroke
epilepsy’.
Secondary outcome measures
(1) Proportion of participants who achieved remission for a pre-
defined period of time (e.g. 12 or 24 months).
(2) Proportion of participants who withdrew from the allocated
treatment within the scheduled follow-up period. This is a com-
posite outcome which takes into account several factors includ-
ing adverse events, compliance, and effectiveness of treatment.We
were particularly interested in the occurrence of side effects for
the different AEDs, which might be physical or neurobehavioural
(e.g. problems with memory, attention and performance skills).
(3) Proportion of participants who had died or become dependent
at the end of the scheduled follow-up period. ’Independent’ indi-
viduals were defined as those who did not require regular physical
assistance from another person for activities of daily living, such as
mobility, dressing, transfers, and feeding. ’Dependent’ individuals
were those who failed to meet one or more of these criteria.
Other outcomes of interest
(1) Quality of life (e.g. using a recognised scoring system such as
SF36 and EuroQol).
(2) Duration of stay for the acute phase of stroke recovery.
(3) ’Optimal’ duration of treatment (i.e. length of time that the
intervention should be continued).
Search methods for identification of studies
This review drew on the search strategies developed for the
Cochrane Epilepsy Group and the Cochrane Stroke Group. We
identified relevant trials in each Group’s Specialised Register on
12 August 2013.
In addition, we searched:
(1) The Cochrane Central Register of Controlled Trials (CEN-
TRAL), The Cochrane Library 2013, Issue 7, using the strategy
outlined in Appendix 1.
(2) MEDLINE (Ovid, 1946 to 12 Augst 2013) using the strategy
outlined in Appendix 2.
We also checked the reference lists of articles retrieved from the
above searches.Where clarification of information was needed, we
attempted to contact the investigators of the relevant studies.
Data collection and analysis
Selection of trials
Two review authors (JK and EW) screened all the titles, abstracts,
and keywords of publications identified by the searches to assess
their eligibility. The review authors were blinded to the names
of the study authors, the institution where the work had been
carried out, and the journal (by printing out the titles, abstracts and
keywords without the author names etc). Publications that clearly
did not meet the inclusion criteria were excluded at this stage.
We obtained a paper copy of the full publication of every study
that was relevant. Both review authors assessed their suitability for
inclusion according to prespecified selection criteria, resolving any
disagreement by discussion.
Assessment of methodological quality
Two review authors independently assessed the methodological
quality of all the studies and recorded the findings. We noted the
important aspects of methodology: study design, type of control,
methodof allocation concealment, completeness of follow-up, and
the presence of blinding for assessments of non-fatal outcomes.
Data extraction
We independently extracted data directly from the one study
which fulfilled our inclusion criteria.
Data analysis
Only one studywas included, hence we performed no data analysis
beyond that performed in the study itself for this review.
R E S U L T S
Description of studies
For the 2010 review, we screened 841 titles, abstracts, and key-
words of publications identified by the searches. Of these, we ob-
tained full-text paper copies for six completed studies (Alvarez-
Sabin 2002; Daniele 2005; Gilad 2007; Pulsinelli 1999; Rowan
2005; Tietjen 1996) and one ongoing study (NCT00542802).
For the 2013 update of this review, we requested the full text of
four further studies (Consoli 2012; Gilad 2011; Messé 2009; Van
Tuijl 2011).
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We excluded all studies except Gilad 2011 as they did not meet
our review inclusion criteria. Please see Characteristics of excluded
studies for details of why each study was excluded. In summary,
two studies did not assess the use of antiepileptic drugs (AEDs)
for the primary or secondary prevention of post-stroke seizures
(Pulsinelli 1999; Tietjen 1996); five studies did not have a placebo/
control group (Alvarez-Sabin 2002; Gilad 2007; Rowan 2005;
SANAD 2007, Messé 2009); three studies were not randomised
controlled trials (Alvarez-Sabin 2002;Daniele 2005;Messé 2009);
and two studies evaluated not only stroke patients but also other
causes of epileptic attacks (Rowan 2005; SANAD2007).However,
in both of these studies, there was no placebo/control group and
we could not separate or extract the data for the stroke subgroup.
One study failed to recruit enough participants due to problems
with the execution of the trial, and we could therefore draw no
conclusion about the ability of the trial drug to prevent post-stroke
seizures (Van Tuijl 2011).
Consoli 2012 reports on the results of the ongoing study
NCT00542802. For the purposes of this review we have added it
as an excluded study; however we may report on it narratively in
the next update of this review.
The only study that was included in this review was Gilad 2011.
This was a prospective randomised, double-blind, placebo con-
trolled trial studying the efficacy of valproic acid versus placebo
in the primary prevention of seizure in 72 adults (over 18 years
of age) with spontaneous non-aneurysmal, non-traumatic intrac-
erebral haemorrhage. The study included patients consecutively
admitted to a neurological centre. They were then randomly al-
located to either the treatment or the placebo group with active
treatment lasting one month; the primary outcome was seizure
occurrence at one year. People with very early seizures (within 24
hours of onset of haemorrhage) were excluded from the study.
Seizure was diagnosed on the basis of eye-witness evidence from
staff, relatives or other eye witnesses.
The methodology of six of the studies excluded from this review
deservemore detailed description because of their relevance (please
see the findings of these studies in Effects of interventions):
(1) Rowan 2005 was an 18-centre, randomised, double-blind,
double-dummy, parallel study of 593 participants over 60 years of
age with newly diagnosed seizures (“geriatric epilepsy”). A mini-
mum of one seizure during the three months preceding enrolment
was required. Participants were randomised to gabapentin, lamot-
rigine or carbamazepine. Therewas no placebo/control group.The
primary outcomemeasure was retention in the trial for 12months.
Secondary endpoints included seizure freedom at 12months, time
to first seizure and drug toxicity. Cerebral infarction was recorded
as the most common primary aetiology of the seizures (29.9%)
followed by arteriosclerosis (15%). There were no data on cere-
bral haemorrhage. A large majority of the study participants had
evidence of underlying vascular disease with diagnoses of hyper-
tension (391/593; 65.9%), stroke (302/593; 50.9%) and cardiac
disease (286/593; 48.2%). Participants had multiple medical con-
ditions and were on an average of seven other medications.
(2) SANAD 2007 was an unblinded randomised controlled trial
in hospital-based outpatient clinics in the United Kingdom (UK).
Arm A recruited 1721 participants for whom carbamazepine was
deemed to be standard treatment, and they were randomly as-
signed to receive carbamazepine, gabapentin, lamotrigine, oxcar-
bazepine, or topiramate in a 1:1:1:1:1 ratio. Participants over the
age of four were recruited, and 108 participants (6.3%) had a his-
tory of stroke or cerebrovascular disease (with no data on propor-
tions of cerebral infarct or haemorrhage). There was no placebo/
control group. Primary outcomes were the time from randomisa-
tion to treatment failure (i.e. stopping the randomised drug due
either to inadequate seizure control or to intolerable side-effects,
or both, or the addition of other antiepileptic drugs, whichever
was the earliest); and the time from randomisation to the achieve-
ment of a one-year period of remission of seizures. Quality of life
and health economics were also assessed. Assessment was by both
intention-to-treat and per protocol.
(3) Gilad 2007 studied the use of lamotrigine monotherapy ver-
sus carbamazepine for people with post-stroke seizure. They in-
cluded 64 participants with ischaemic stroke in their study, and
these were randomised in a 1:1 ratio to either lamotrigine or car-
bamazepine monotherapy. Only those participants with a middle
cerebral artery distribution stroke on computed tomography (CT)
or magnetic resonance imaging (MRI) were included. They were
followed up prospectively for 12 months. Participants with status
epilepticus ormore than two seizures within the first 24 hours were
excluded from the study (two participants). The primary endpoint
of the study was a second seizure or reaching the end of the 12-
month follow-up without seizures. The tolerability of the study
medications was evaluated as a secondary endpoint. Limitations
of the study are that there was no placebo/control group, partici-
pant numbers were small, the study was not double-blinded and
participants with seizures within the first 24 hours were excluded.
(4) Daniele 2005 studied the use of levetiracetam monotherapy
for treating early post-stroke seizures. They included 54 partici-
pants in their study, with 34 participants (29 with ischaemic and 5
with haemorrhagic stroke) receiving levetiracetam and 20 partici-
pants as controls. It is unclear how the participants were selected
and what treatments the control group received. Participants were
followed up for a period of 12 months. The participants were not
randomised, the study was not blinded, and participant numbers
were small.
(5) Alvarez-Sabin 2002 studied the long-term efficacy and toler-
ability of gabapentin in 71 prospective participants (48 with is-
chaemic and 23 with haemorrhagic stroke) with a first post-stroke
seizure. Participants were followed up for at least a year with a
mean follow-up time of 30 months. The participants were not
randomised, there was no placebo/control group, and participant
numbers were small.
6) Messé 2009 studied whether giving people who had sustained
intracranial haemorrhage (ICH) a novel neuroprotective medica-
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tion (AED) early was associated with poor outcome at day 90 -
defined as a modified Rankin Score of five (severely disabled) or
six (dead). Data were analysed from the placebo arm only of the
Cerebral Hemorrhage and NXY-059 Trial (CHANT). CHANT
was an international multicentre randomised trial that enrolled
participants over the age of 18within six hours of the onset of acute
ICH. Three hundred and three participants were entered into the
placebo arm of this trial: eight were excluded as they were already
on AEDs. As only one arm of this trial was studied, participants
in this subanalysis were not randomised and there was no control
group.
Risk of bias in included studies
The Gilad 2011 included only 72 participants. This small sample
size may introduce bias to the results, although this will have been
minimised by the randomisation process.
Seizureswere diagnosed on the basis of eye-witness evidence. There
was no continuous electroencephalographic (EEG) monitoring
during this study; EEG was only done if definite seizures were
observed, or if the diagnosis of seizure was in doubt (unexplained
confusion, depressed mental status). Therefore, some seizure ac-
tivity may have gone unnoticed.
In addition, the study excluded participants who experienced
seizure within 24 hours of onset of intracranial haemorrhage. The
group studied may therefore have been those at lower risk of
seizures than those excluded, which could potentially have given
falsely optimistic results in terms of seizure prevention at one year
and in the secondary outcome of improvement in National Insti-
tutes of Health Stroke Scale (NIHSS) score at one year.
Participants in the placebo group were treated with an anticon-
vulsant if they experienced a seizure. No comment is made in the
study about whether participants in the treatment group were also
given an increased dose or additional anticonvulsant if they experi-
enced seizure. If both groups of participants experiencing seizures
did receive anticonvulsants, this is a potential source of bias.
However, best medical practice is to treat seizures if they were
recurrent or did not quickly self terminate. There would be ethical
implications in not doing this for both groups regardless of their
study status.
Based on the analysis included in the risk of bias table (below) there
is a low risk of bias in this study on the basis of the information
available.
Effects of interventions
Gilad 2011 found that of 84 participants initially included, five
suffered immediate seizures and seven were lost to follow-up.
Therefore, 72 participants completed the study, 36 in each arm.
There was no statistically significant difference between the group
receiving valproic acid and that receivingplacebo in terms of demo-
graphics, co-morbidities or the primary outcome of seizure occur-
rence at one year. There was a non-statistically significant reduc-
tion in early seizures (less than 14 days after onset of haemorrhage)
in the treatment group compared to placebo. There was a statisti-
cally significant benefit in the secondary outcome of NIHSS score
at one year in the valproic acid group compared to the placebo
group (treatment group 4.4 4.1, placebo group 8.6 6.1, P =
0.002).
The results of six of the excluded studies are mentioned because of
their relevance to this area (please see the methodologies for these
studies in Description of studies):
(1) Rowan 2005 found that of the 590 participants enrolled and
not terminated due to administrative reasons, 276 (46.8%) com-
pleted one year in the trial. Tolerability of the three drugs was
however different. There were more early terminators in the car-
bamazepine group (64.5%) than in the groups taking lamotrigine
(44.3%) or gabapentin 51% (P = 0.0002). In paired-group com-
parisons carbamazepine had more early terminators than either
gabapentin (P = 0.008) or lamotrigine (P < 0.0001). Few partici-
pants terminated the study due to uncontrolled seizures and there
were no differences between the three groups. The majority of
the participants in the carbamazepine group left the study due to
adverse reactions. Hypersensitivity (rash of any degree) was more
frequent with carbamazepine than with lamotrigine (P = 0.007).
Six of the seven participants hospitalised for hypersensitivity reac-
tions were in the carbamazepine group. Hyponatraemia was also
more common in the carbamazepine group. Gabapentin partici-
pants were significantly more likely to gain weight over the first 12
months than those on carbamazepine (P = 0.002) or lamotrigine
(P = 0.001). Water retention was also significantly greater with
gabapentin than with carbamazepine (P = 0.004) or lamotrigine
(P = 0.02).
There were no significant differences in the seizure-free rate at 3, 6
and 12 months between the three groups. Seizure-free rates were
63.2% at three months (lamotrigine 63.1%, gabapentin 62.2%,
carbamazepine 64.8%; P = 0.93), 58.6% at six months (lamotrig-
ine 56.6%, gabapentin 56.6%, carbamazepine 64.8%; P = 0.39)
and 53.3% at 12 months (lamotrigine 51.4%, gabapentin 56.6%,
carbamazepine 64.3%; P = 0.09). When seizures occurring dur-
ing the six-week period of drug titration are excluded, 63.4% of
participants were seizure-free at 12 months (lamotrigine 61.3%,
gabapentin 60%, carbamazepine 71.4%; P = 0.27). There were
no significant differences in time to first, second, fifth and tenth
seizures between the three groups. When looking at seizure-free
retention, participants on lamotrigine did better at three and six
months after seizures occurring during the six-week titration pe-
riod were excluded. However, the differences at 12 months were
not significant (overall P value = 0.16).
(2) SANAD 2007: for time to treatment failure, lamotrigine was
significantly better than carbamazepine, gabapentin and topira-
mate, and had a non-significant advantage compared with oxcar-
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bazepine. For time to 12-month remission, carbamazepine was
significantly better than gabapentin, and a non-significant advan-
tage for carbamazepine against lamotrigine, topiramate and oxcar-
bazepine was observed. Longer-term per protocol analyses at two
and four years demonstrated non-inferiority of lamotrigine com-
pared with carbamazepine in the proportion of people achieving
a 12-month remission. Around half of all participants reported
adverse events at some point in the study. For the intention-to-
treat population, lamotrigine was the drug with the least number
of participants reporting adverse events (45% intention-to-treat,
37% per protocol) and topiramate the most (53% intention-to-
treat, 49% per protocol). There were no significant differences in
the quality of life between the five groups. The authors concluded
that lamotrigine is clinically better than carbamazepine for time-
to-treatment-failure outcomes and was therefore a cost-effective
alternative for people diagnosed with partial onset seizures.
(3) Gilad 2007 found that more participants in the lamotrigine
group were seizure-free (72%) versus those in the carbamazepine
group (44%; P = 0.06). Significantly fewer participants withdrew
from the study due to adverse events in the lamotrigine group
(3%) compared with the carbamazepine group (31%; P = 0.02).
(4)Daniele 2005 observed the recurrence of seizures in two (5.8%)
of the 34 participants treated with levetiracetam compared with
three (15%) of the 20 participants in the control group.
(5) Alvarez-Sabin 2002 showed that 13 (18.3%) of the participants
treated with gabapentin experienced one or more seizures during
follow-up. Gabapentin treatment was discontinued in two people
due to inadequate seizure control. Side effects were recorded in
27 cases (38%). The most common side effects were drowsiness
(17%), dizziness (14%), headache and fatigue (7%), and nausea
and vomiting (6%). Only two participants withdrew from the
study due to drug side effects.
6) Messé 2009 defined poor outcome at day 90 as a modified
Rankin Scale score of five or six (severely disabled or dead). Eighty-
two participants (28%) had a poor outcome at day 90; early ini-
tiation of AEDs was significantly associated with poor outcome
after adjustment for other known predictors of outcome after in-
tracranial haemorrhage (age, initial haematoma volume, presence
of intraventricular blood, initial Glasgow coma score, and prior
warfarin use).
D I S C U S S I O N
This review aimed to assess the effects of antiepileptic drugs
(AEDs) for the primary and secondary prevention of seizures after
stroke. Using our review criteria, only one of the selected studies
could be included for further analysis. This study of 72 partici-
pants did not produce a statistically significant result when com-
paring valproic acid with placebo for the primary prevention of
seizures after spontaneous non-aneurysmal, non-traumatic intrac-
erebral haemorrhage. However, the treatment group had a lower,
non-statistically significant incidence of early seizures (less than 14
days after onset of haemorrhage) compared to the placebo group.
The valproic acid treatment group also demonstrated a statistically
significant benefit in the secondary outcome of National Institutes
of Health Stroke Scale (NIHSS) score at one year compared to the
placebo group. This supports the hypothesis of a neuroprotective/
neuro-remodelling effect of valproic acid. Whether these results
can be translated to apply to other forms of stroke (e.g. ischaemic,
subarachnoid haemorrhage) is not certain.
We did, however, find three interesting randomised controlled tri-
als comparing a number of different AEDs. One study was per-
formed in older adults (mean age 72 years) with a mixture of di-
agnoses including stroke (Rowan 2005); another study was per-
formed in children and younger adults with a mixture of diagnoses
including stroke (SANAD2007); and the last studywas performed
in people with stroke only (Gilad 2007). The findings from these
three studies suggest that lamotrigine may be a clinically more
useful AED than carbamazepine, but this finding cannot be gen-
eralised to the post-stroke population as a whole. Results from the
non-randomised Daniele 2005 also suggest that it may be worth
evaluating levetiracetam in future randomised controlled trials of
seizures after stroke.
The management of post-stroke seizures therefore remains con-
troversial. One observational study reported that during a four-
year follow-up period half of all people who received AEDs after
a first post-stroke seizure had at least one seizure relapse (Hauser
1993). European guidelines recommend the use of AEDs to pre-
vent recurrent seizures after stroke but prophylactic administra-
tion to people with stroke who have not experienced a seizure
is not recommended (EUSI 2003). American guidelines are less
precise, simply stating that: “there are no data about the utility of
prophylactic administration of AEDs after stroke”.
Due to the lack of trial evidence on the efficacy of AEDs in
the treatment of post-stroke seizures, clinical guidelines are often
based on the established management of seizures that may com-
plicate any acute neurological illness (ASA 2003). Some other ex-
perts go further and recommend that early and late post-stroke
seizures should receive long-term prophylactic treatment with
AEDs (Asconape 1991; Camilo 2004). In some countries such as
the United Kingdom, sodium valproate remains a very popular
AED for the treatment of post-stroke seizures (Stephen 2003),
although there is no conclusive evidence to support this practice
(SANAD 2007).
Neurologists and stroke physicianswill probably continue to strug-
gle with the question of whether one isolated post-stroke seizure
(especially an early seizure) requires immediate treatment with
AEDs, and if so, which drug(s) should be initiated, at what dosage,
and for how long. Many clinicians would agree that repeated
unprovoked post-stroke seizures probably require treatment with
AEDs, but again there is no good evidence to informwhich drug(s)
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should be initiated, at what dosage, and for how long.
Furthermore, there is some evidence that there may be potential
risks with using AEDs in the post-stroke recovery period. For ex-
ample, there are concerns that the use of phenytoin, phenobarbi-
tal, and benzodiazepines in the post-stroke period may adversely
affect motor recovery (Goldstein 1990).
Summary of main results
This review aimed to assess the effects of antiepileptic drugs
(AEDs) for the primary and secondary prevention of seizures after
stroke. Using our review criteria, only one study could be included
for further analysis. This study of 72 participants did not pro-
duce a statistically significant result when comparing valproic acid
with placebo for the primary prevention of seizures after sponta-
neous non-aneurysmal, non-traumatic intracerebral haemorrhage.
However, the treatment group had a lower, non-statistically sig-
nificant incidence of early seizures (less than 14 days after onset
of haemorrhage) compared to the placebo group. The valproic
acid treatment group also demonstrated a statistically significant
benefit in the secondary outcome of National Institutes of Health
Stroke Scale (NIHSS) score at one year compared to the placebo
group. This supports the hypothesis of a neuroprotective/neuro-
remodelling effect of valproic acid. Whether these results can be
translated to apply to other forms of stroke (e.g. ischaemic, sub-
arachnoid haemorrhage) is not certain.
We did, however, find three interesting randomised controlled tri-
als comparing a number of different AEDs. One study was per-
formed in older adults (mean age 72 years) with a mixture of di-
agnoses including stroke (Rowan 2005); another study was per-
formed in children and younger adults with a mixture of diag-
noses including stroke (SANAD 2007 ); and the last study was
performed in people with stroke only (Gilad 2007). The findings
from these three studies suggest that lamotriginemay be a clinically
more useful AED than carbamazepine, but this finding cannot
be generalised to the post-stroke population as a whole. Results
from the non-randomised Daniele 2005 also suggest that it may
be worth evaluating levetiracetam in future randomised controlled
trials of seizures after stroke.
The management of post-stroke seizures therefore remains con-
troversial. One observational study reported that during a four-
year follow-up period half of all people who received AEDs after
a first post-stroke seizure had at least one seizure relapse (Hauser
1993). European guidelines recommend the use of AEDs to pre-
vent recurrent seizures after stroke but prophylactic administra-
tion to people with stroke who have not experienced a seizure is
not recommended (EUSI 2003).
Overall completeness and applicability of
evidence
Due to the lack of trial evidence on the efficacy of AEDs in the
treatment of post-stroke seizures, clinical guidelines are oftenbased
on the established management of seizures that may complicate
any acute neurological illness (ASA 2003 ). Some other experts
go further and recommend that early and late post-stroke seizures
should receive long-term prophylactic treatment with AEDs (As-
conape 1991; Camilo 2004). In some countries such as the United
Kingdom, sodium valproate remains a very popular AED for the
treatment of post-stroke seizures (Stephen 2003), although there
is no conclusive evidence to support this practice (SANAD2007).
Neurologists and stroke physicianswill probably continue to strug-
gle with the question of whether one isolated post-stroke seizure
(especially an early seizure) requires immediate treatment with
AEDs, and if so, which drug(s) should be initiated, at what dosage,
and for how long. Many clinicians would agree that repeated
unprovoked post-stroke seizures probably require treatment with
AEDs, but again there is no good evidence to informwhich drug(s)
should be initiated, at what dosage, and for how long.
Furthermore, there is some evidence that there may be potential
risks with using AEDs in the post-stroke recovery period. For ex-
ample, there are concerns that the use of phenytoin, phenobarbi-
tal, and benzodiazepines in the post stroke period may adversely
affect motor recovery (Goldstein 1990).
Quality of the evidence
Due to the lack of high quality clinical evidence available we are
not able to answer the question ‘is there evidence to support the use
of antiepileptic drugs for the primary and secondary prevention of
seizures after stroke?’ However, the one included study which did
attempt to address this question, Gilad 2011, was well designed
and with a low risk of bias. Unfortunately it did not provide a
statistically significant conclusion. Therefore further research into
this area is needed.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Currently, there is insufficient evidence to support the routine
use of antiepileptic drugs (AEDs) for the primary or secondary
prevention of seizures after stroke.
Implications for research
More research is needed to assess the efficacy and tolerability of
antiepileptic drugs for the primary and secondary prevention of
seizures after stroke. Future studies should be randomised, dou-
ble-blind, double-dummy, comparing one or more AEDs with a
placebo. Such studies should aim to recruit large numbers of par-
ticipants and assess clinically meaningful outcome measures, e.g.
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seizure-free periods and withdrawal rates from the allocated AED
within the scheduled follow-up period. Other important aspects
also need to be answered by future studies, including, for example,
optimal timing and duration of AED treatment.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Gilad 2011
Methods Study design: prospective randomised, double-blind, placebo-controlled study
Purpose: to assess the occurrence of seizure and neurological outcome in sICH patients
who were treated with valproic acid or a placebo for 1 month and follow-up of 1 year
Methods: CT brain scan at baseline, seizures diagnosed on the basis of eye-witness
evidence from staff or relatives/other eye witnesses. NIHSS at baseline and at 1 year
Participants Inclusion criteria: consecutive patients with spontaneous non-aneurysmal, non-trau-
matic intracerebral haemorrhage admitted to a neurological centre. They were then ran-
domly allocated to either the treatment or placebo group
Exclusion criteria: patients with early (less than 24 hours after onset) seizures or those
lost to follow-up (due to other illness or withdrawal of consent for inclusion)
Interventions Oral valproic acid 400mg twice daily or placebo at a corresponding dosage for an active
therapy period of one month
Outcomes Primary outcome: seizure occurrence at 1 year of follow-up.
Secondary outcome: NIHSS score at 1 year of follow-up.
Notes No information provided regarding funding or conflicts of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A computer-generated randomisation list
was used, such that each consecutive pa-
tient recruited was assigned to treatment
according to the list
Allocation concealment (selection bias) Unclear risk No information provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information provided.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data.
Selective reporting (reporting bias) Unclear risk No information provided.
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Gilad 2011 (Continued)
Other bias Low risk The study appears to be free of other
sources of bias.
CT: computed tomography
NIHSS: National Institutes of Health Stroke Scale
sICH: symptomatic intracranial haemorrhage
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alvarez-Sabin 2002 Not a randomised controlled trial; no placebo arm.
Consoli 2012 No placebo arm.
Daniele 2005 Not a randomised controlled trial; “control group” but no mention of placebo arm
Gilad 2007 No placebo arm.
Messé 2009 Not a randomised controlled trial; analysis of data from placebo arm only of a randomised controlled trial of
an unproven neuroprotective medication
Pulsinelli 1999 Investigated the efficacy of fosphenytoin in the treatment of acute ischaemic stroke but not to prevent or treat
post-stroke seizures
Rowan 2005 Investigated the efficacy of AEDs in “geriatric epilepsy” - data for people with stroke could not be extracted
and analysed separately; no placebo arm
SANAD 2007 Investigated the efficacy of AEDs in focal epilepsy - data for people with stroke could not be extracted and
analysed separately; no placebo arm
Tietjen 1996 Investigates the safety of phenytoin in the treatment of acute ischaemic stroke but not to prevent or treat post-
stroke seizures
Van Tuijl 2011 Not enough participants recruited therefore no relevant conclusion could be drawn
AED: antiepileptic drug
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Characteristics of ongoing studies [ordered by study ID]
NCT00542802
Trial name or title Levetiracetam versus carbamazepine in post-stroke late onset crisis (EpIc)
Methods Official title: Multicenter, comparative, randomized, open trial to evaluate efficacy and safety of levetiracetam
versus carbamazepine in post stroke late onset crisis
Study design: treatment, randomised, open label, active control, parallel assignment, interventional study
Methods: EEG at baseline and 1-year follow-up; cognitive function and quality of life evaluation at 1-year
follow-up; and compare seizure frequency at 1-year follow-up
Participants Inclusion criteria: people having a stroke (ischaemic and haemorrhagic) showing (1) subsequent seizure 14
days up to 3 years after stroke.
Exclusion criteria: severe stroke patients with Rankin scale > 3; life expectancy of < 12 months; screened more
than 15 days after first seizure; with a diagnosed epilepsy; with clear evidence of myoclonic seizures; with
contraindication to levetiracetam
Interventions Levetiracetam versus carbamazepine
Outcomes Primary outcome: number of participants free from post-stroke recurrent crisis (seizures)
Secondary outcome: to compare retention time of levetiracetam vs carbamazepine since first intake throughout
treatment period; to compare time to second seizure in both treatments; to evaluate differences in cognitive
function and in quality of life in levetiracetam and carbamazepine participants having post-stroke seizures
at the end of treatment period; evaluate EEG changes obtained at the end of treatment period compared
with baseline; to compare seizure frequency in levetiracetam and carbamazepine groups throughout treatment
period; to evaluate the safety of levetiracetam versus carbamazepine throughout the treatment period
Starting date 2007
Contact information Contact person: Sara Papetti. Email: spapetti@gbpharmaservices.it
Notes Principle investigator: Domenico Consoli. Email: domco@tiscali.it
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 (epilep*)
#2 MeSH descriptor Epilepsy explode all trees
#3 (seizure*)
#4 MeSH descriptor Seizures explode all trees
#5 convulsion*
#6 anticonvulsant*
#7 MeSH descriptor Anticonvulsants explode all trees
#8 antiepilep*
#9 phenytoin
#10 valpro*
#11 carbamazepine
#12 ethosuximide
#13 phenobarbit*
#14 MeSH descriptor Phenobarbital explode all trees
#15 primidone
#16 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15)
#17 MeSH descriptor Cerebrovascular Disorders explode all trees
#18 MeSH descriptor Basal Ganglia Cerebrovascular Disease explode all trees
#19 MeSH descriptor Brain Ischemia explode all trees
#20 MeSH descriptor Carotid Artery Diseases explode all trees
#21 MeSH descriptor Brain Infarction explode all trees
#22 MeSH descriptor Hypoxia-Ischemia, Brain explode all trees
#23 MeSH descriptor Intracranial Arterial Diseases explode all trees
#24 MeSH descriptor Intracranial Arteriovenous Malformations explode all trees
#25 MeSH descriptor Intracranial Embolism explode all trees
#26 MeSH descriptor Intracranial Hemorrhages explode all trees
#27 MeSH descriptor Vasospasm, Intracranial explode all trees
#28 (#17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27)
#29 (stroke* or poststroke* or cva)
#30 (cerebrovascular*) or (cerebral vascular)
#31 cerebral or cerebellar or brainstem or vertebrobasilar
#32 (infarct* or ischemi* or ischaemi* or thrombo* or apoplexy or emboli*)
#33 (#31 AND #32)
#34 cerebral or intracerebral or intracranial or parenchymal
#35 brain or intraventricular or brainstem or cerebellar
#36 infratentorial or supratentorial
#37 (#34 OR #35 OR #36)
#38 haemorrhage or hemorrhage or haematoma or hematoma or bleeding or aneurysm
#39 (#37 AND #38)
#40 (#39 OR #28 OR #29 OR #30 OR #33)
#41 (#40 AND #16)
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Appendix 2. MEDLINE search strategy
We received guidance from theCochrane StrokeGroup for the stroke section of this strategy. The filter to identify randomized controlled
trials was taken from Lefebvre 2008.
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. clinical trials as topic.sh.
6. randomly.ab.
7. trial.ti.
8. 7 or 5 or 2 or 6 or 1 or 4 or 3
9. (animals not (humans and animals)).sh.
10. 8 not 9
11. epilep$.tw.
12. exp Epilepsy/
13. seizure$.tw.
14. exp Seizures/
15. convulsion$.tw.
16. anticonvulsant$.tw.
17. exp Anticonvulsants/
18. antiepilep$.tw.
19. phenytoin.tw.
20. valpro$.tw.
21. carbamazepine.tw.
22. ethosuximide.tw.
23. phenobarbit$.tw.
24. exp Phenobarbital/
25. primidone.tw.
26. or/11-25
27. Cerebrovascular Disorders/
28. exp Basal Ganglia Cerebrovascular Disease/
29. exp Brain Ischemia/
30. exp Carotid Artery Diseases/
31. exp Brain Infarction/
32. exp Hypoxia-Ischemia, Brain/
33. exp Intracranial Arterial Diseases/
34. Intracranial Arteriovenous Malformations/
35. exp Intracranial Embolism/
36. exp Intracranial Hemorrhages/
37. Vasospasm, Intracranial/
38. 34 or 32 or 31 or 27 or 35 or 37 or 33 or 29 or 36 or 28 or 30
39. (stroke$ or poststroke or cva).tw.
40. (cerebrovascular$ or cerebral vascular).tw.
41. (cerebral or cerebellar or brainstem or vertebrobasilar).tw.
42. (infarct$ or isch?emi$ or thrombo$ or apoplexy or emboli$).tw.
43. 41 and 42
44. (cerebral or intracerebral or intracranial or parenchymal).tw.
45. (brain or intraventricular or brainstem or cerebellar).tw.
46. (infratentorial or supratentorial).tw.
47. 45 or 44 or 46
48. (haemorrhage or hemorrhage or haematoma or hematoma or bleeding or aneurysm).tw.
49. 48 and 47
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50. 49 or 38 or 39 or 43 or 40
51. 10 and 26 and 50
WH A T ’ S N E W
Last assessed as up-to-date: 12 August 2013.
Date Event Description
12 August 2013 New search has been performed Searches updated 12 August 2013.
12 August 2013 New citation required but conclusions have not changed One new study has been added (Gilad 2011). Conclu-
sions remain unchanged.
C O N T R I B U T I O N S O F A U T H O R S
Professor Joseph Kwan and Dr Emma Wood performed the original bibliographic searches, identified the studies, and assessed the
methodological quality of the studies. Both review authors contributed to the writing of the manuscript with Professor Joseph Kwan
being the main contributing author. This 2013 review update has been performed by Dr Lucy Sykes with Professor Joseph Kwan.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• Cochrane Incentive Scheme, UK.
Cochrane Incentive Scheme leading to an award of £5000 upon completion of this review
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We made a slight amendment to the search terms that were set out in the protocol, as ’Cerebrovascular Accident’ is no longer used as
an index term in MEDLINE. Please see Appendices for details.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anticonvulsants [∗therapeutic use]; Primary Prevention [methods]; Randomized Controlled Trials as Topic; Secondary Prevention;
Seizures [etiology; ∗prevention & control]; Stroke [∗complications]
MeSH check words
Aged; Humans
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